Testing effectiveness (Phase 2)WithdrawnNCT04007588
What this trial is testing
A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma
Who this might be right for
Melanoma Stage IIIMelanoma Stage IV
Dana-Farber Cancer Institute